Contemporary Pediatrics week in review: FDA approved sickle cell treatments, pediatric pneumonia, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, December 4 to Friday, December 8, 2023), and click on each link to read and watch anything you may have missed.
1.) FDA approves pair of gene therapies to treat patients with sickle cell disease
Sickle cell disease (SCD) patients aged 12 years and up can now be treated with exa-cel and lovo-cel, following simultaneous approval from the FDA on December 8, 2023.
Click here for the full article.
2.) Discussing the attention pediatric pneumonia has received amid rising cases
Tina Tan, MD, FAAP, FIDSA, FPIDS, explains that the recent uptick in pediatric pneumonia cases across the country, which some have called "white lung syndrome," is nothing new, and there is no cause for panic.
Click here to watch the full interview.
3.) Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Click here for the full article.
4.) RSV Roundtable: What clinicians are witnessing in terms of RSV incidence
Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.
Click here to watch the first episode of our RSV Roundtable.
5.) Link between autism spectrum disorder risk and infertility
To determine the association between infertility and fertility treatment with ASD risk, investigators conducted a retrospective, population-based study using health data from Ontario, Canada.
